A comprehensive view of european medicines agency (ema). This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Eisai and Biogen disappointed by EMA's negative opinion on lecanemab for early Alzheimer's; the humanized anti-amyloid-beta monoclonal antibody was under review for mild cognitive impairment
Published: July 26, 2024 by Biogen Inc.
CHMP recommends marketing authorization in EU for Pfizer and BioNTech's Omicron JN.1-adapted monovalent COVID-19 vaccine for individuals six months of age and older
Published: June 27, 2024 by Pfizer Inc.
GSK Group (GlaxoSmithKline) Advances Oncology and Blood Cancer Therapies with EMA Validation and Japan MHLW Approval, Champions Sustainability and Advocates for Preventative Vaccinations
Published: June 24, 2024 by Industry Intelligence Inc.
European Medicines Agency validates Bristol Myers' application for Opdivo nivolumab plus Yervoy ipilimumab for the first-line treatment of adult patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer
Published: May 06, 2024 by Bristol-Myers Squibb Co.
Amgen submits marketing authorization application to the European Medicines Agency for teprotumumab treatment for moderate to severe thyroid eye disease in adults; if approved, teprotumumab would be the first approved medicine for TED in the EU
Published: April 29, 2024 by PharmaBiz (India)

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count